iShares S&P Small-Cap 600 Value

Most Recent

  • uploads///
    Earnings Report

    Acquisitions Could Help Supervalu’s 3Q18 Top Line

    Wall Street expects Supervalu’s (SVU) 3Q18 total sales to increase 34% YoY to $4 billion. The sales growth will likely be driven by its wholesale business.

    By Sonya Bells
  • uploads///Reveue and earnings
    Company & Industry Overviews

    What Affected Flotek Industries’ Earnings in 4Q16

    In terms of operating income, FTK’s Energy Chemistry Technologies segment fell 34% from 4Q15 to 4Q16.

    By Alex Chamberlin
  • uploads///EPS
    Earnings Report

    What Do Analysts Expect from Tidewater’s Fiscal 3Q17 Earnings?

    In fiscal 3Q17, analysts expect an ~$1.16 adjusted loss per share for Tidewater. Analysts expect Tidewater’s adjusted loss to fall in the coming quarter.

    By Alex Chamberlin
  • uploads///Segment Revenue
    Earnings Report

    Will Strategic Alternatives Shape Flotek Industries in 2017?

    The Energy Chemistry Technology segment accounted for 76% of Flotek Industries’ revenues in 1Q17. The segment’s revenues rose 36% in 1Q17—compared to 1Q16.

    By Alex Chamberlin
  • uploads///Volume and Well growth
    Miscellaneous

    How Is Flotek Industries Positioned to Grow in 2017?

    In 2017, crude oil prices have lost nearly 16%, after recovering 45% in 2016.

    By Alex Chamberlin
  • uploads///Revenue and Earnings
    Company & Industry Overviews

    Which of Flotek Industries’ Segments Has Weakened the Most?

    FTK’s segment-wise income We discussed Flotek Industries’ (FTK) revenue in the previous part of this series. Operating income–wise, FTK’s Energy Chemistry Technologies segment fell 56.6% between 3Q15 and 3Q16. In contrast, its Consumer and Industrial Chemistry Technologies segment’s operating income rose ~41%. Between 3Q15 and 3Q16, Flotek Industries’ US revenue fell ~21%. Its revenue from […]

    By Alex Chamberlin
  • uploads///Segments
    Basic Materials

    What Affected Flotek Industries in 2Q17?

    We’ll now look into Flotek Industries’ (FTK) segment performance in 2Q17. Revenues in the Energy Chemistry Technology (or ECT) segment rose 2% in 2Q17 over a year ago.

    By Alex Chamberlin
  • uploads///Graph
    Company & Industry Overviews

    This Could Be a Solid Growth Driver for Myriad Genetics in 2018

    Myriad Genetics (MYGN) announced the U.S. Food and Drug Administration’s (or FDA) acceptance of its supplementary premarket approval application for BRACAnalysis CDx, a DNA sequencing companion diagnostic test.

    By Margaret Patrick
  • uploads///EPS
    Basic Materials

    Why Flotek Industries’ 4Q17 Earnings Beat Estimates

    Flotek Industries (FTK) released its 4Q17 financial results on February 20. The company recorded operating revenues of $72.5 million in 4Q17, up 2.7% from the $70.6 million recorded in 4Q16.

    By Alex Chamberlin
  • uploads///Segment Rev Change
    Earnings Report

    Which Factors Affected Flotek Industries in 3Q16?

    Revenues for Flotek’s (FTK) Energy Chemistry Technologies segment fell 25.0% in 3Q16 over a year ago. The segment’s operating income fell 56.6%.

    By Alex Chamberlin
  • uploads///FCF
    Company & Industry Overviews

    Why Was Tidewater’s Free Cash Flow Negative?

    In the first six months of 2017, Tidewater’s free cash flow was -$10 million. Tidewater generated positive free cash flow in fiscal 2016.

    By Alex Chamberlin
  • uploads///FTK
    Basic Materials

    Flotek Industries’ Revenues: What to Expect in 1Q18

    In 1Q18, Wall Street analysts expect to see 1.2% revenue growth for Flotek Industries compared to 4Q17.

    By Alex Chamberlin
  • uploads///Spectrum Pharmaceuticals Revenue Trend
    Company & Industry Overviews

    Chart in Focus: Spectrum Pharmaceuticals’ Financials

    In 3Q17, Spectrum Pharmaceuticals (SPPI) raised $114.0 million from the sale of 12.6 million shares through its security offering program.

    By Kenneth Smith
  • uploads///Graph
    Company & Industry Overviews

    Myriad Genetics’ GeneSight: A Major Growth Driver in 2018?

    In the first quarter of fiscal 2018, Myriad Genetics’ (MYGN) GeneSight reported revenues of $28.8 million, which is a YoY growth of 54% and a sequential growth of 12%.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Vabomere: Major Addition to The Medicines Company’s Portfolio?

    On August 29, 2017, the FDA approved The Medicines Company’s (MDCO) Vabomere for treating adulating patients suffering with complicated urinary tract infections.

    By Margaret Patrick
  • uploads///
    Earnings Report

    Supervalu Focuses on Wholesale to Boost Sales

    For the second quarter of fiscal 2018, Wall Street has projected Supervalu’s (SVU) total sales landing around $3.78 billion.

    By Sonya Bells
  • uploads///Segments
    Miscellaneous

    These Factors Are Affecting Flotek Industries the Most

    Flotek Industries’ (FTK) Energy Chemistry Technology segment saw a 36% YoY (year-over-year) increase in revenues in 1Q17.

    By Alex Chamberlin
  • uploads///
    Earnings Report

    Wholesale Drives SuperValu’s Top Line, Retail Stays Muted

    Wholesale drives SuperValu’s top line As discussed, SuperValu (SVU) reported its 4Q17 results on April 25. The company returned to growth after several quarters of sales decline. The company’s wholesale segment was the key driver of its 1Q17 top line. Sales from this segment stood at $1.8 billion, up 3% YoY (year-over-year). Revenue growth was […]

    By Sonya Bells
  • uploads///
    Miscellaneous

    Wall Street Expects a 45% Jump in SVU’s Stock Price

    Wall Street is quite positive on Supervalu’s (SVU) stock. Analysts are expecting a 45% rise in SVU’s stock price over the next 12 months.

    By Sonya Bells
  • uploads///
    Miscellaneous

    How Has Supervalu’s Stock Performed?

    After falling around 30% in 2016, Supervalu’s (SVU) stock continues to be in the red in 2017.

    By Sonya Bells
  • uploads///Segments
    Company & Industry Overviews

    What’s Affecting Flotek Industries’ Revenue

    We’ll now look into Flotek Industries’ (FTK) segment performance in 4Q16. The Energy Chemistry Technologies segment accounted for 68% FTK’s 4Q16 revenues.

    By Alex Chamberlin
  • uploads///Broker Recommendations
    Earnings Report

    Wall Street’s Forecasts for Tidewater after Its Fiscal 3Q17 Earnings

    According to Reuters, none of the analysts tracking Tidewater (TDW) recommended a “buy” or any equivalent for the stock.

    By Alex Chamberlin
  • uploads///Estimates
    Earnings Report

    Will Tidewater’s Fiscal 3Q17 Earnings Disappoint?

    In fiscal 3Q17, analysts expect $1.16 adjusted loss per share for Tidewater (TDW). Wall Street analysts expect Tidewater’s adjusted loss to deteriorate.

    By Alex Chamberlin
  • uploads///IV
    Earnings Report

    Analyzing Tidewater’s Implied Volatility

    Since Tidewater’s fiscal 2Q17 financial results were announced on November 7, 2016, its implied volatility has decreased from 258% to the current level.

    By Alex Chamberlin
  • uploads///Segment Revenue
    Earnings Report

    What Are Flotek Industries’ Growth Drivers for 4Q16?

    Revenues in Flotek Industries’ (FTK) Energy Chemistry Technologies segment fell 25% in 3Q16 over 3Q15.

    By Alex Chamberlin
  • uploads///FCF
    Company & Industry Overviews

    The Effect of a Credit Facility Agreement on Flotek’s Capex

    Flotek Industries’ operating cash flow In this article, we’ll analyze how Flotek Industries’ (FTK) operating cash flow has trended over the past few quarters. We’ll also discuss how its capital expenditure (capex) affected its free cash flow (or FCF). Flotek Industries’ cash from operating activities (or CFO) fell 62% between 3Q15 and 3Q16. FTK generated […]

    By Alex Chamberlin
  • uploads///Segment Rev
    Company & Industry Overviews

    What’s Affecting Flotek Industries?

    Flotek Industries’ revenue growth by segments Flotek Industries’ (FTK) Energy Chemistry Technologies segment accounted for 61% of FTK’s 3Q16 revenue. Revenue in this segment fell 25% between 3Q15 and 3Q16. Flotek Industries makes up 0.15% of the iShares S&P Small-Cap 600 Value ETF (IJS). The energy sector accounts for 4.3% of IJS. The Consumer and […]

    By Alex Chamberlin
  • uploads///Debt Maturity
    Company & Industry Overviews

    ODH’s Credit Rating Downgrade: How’s the OFS Industry Coping?

    On November 29, Fitch Rating downgraded the credit rating for Offshore Drilling Holding SA—a Mexican offshore driller.

    By Alex Chamberlin
  • uploads///Debt Maturity
    Company & Industry Overviews

    Tidewater Dodges the Bankruptcy Bullet: For How Long?

    On November 11, Tidewater (TDW) received a second extension of waivers against debt covenant compliances until January 27, 2017.

    By Alex Chamberlin
  • uploads///part__q
    Earnings Report

    Why Did H.B. Fuller’s Asia Pacific Revenues Rise in 3Q16?

    H.B. Fuller’s (FUL) Asia Pacific segment reported revenues of $57.5 million in 3Q16. This represents 11.2% of the company’s total revenue.

    By Peter Neil
  • uploads///part__q
    Earnings Report

    Why Did H.B. Fuller Miss 3Q16 Revenue Estimates?

    Analysts had estimated that H.B. Fuller’s (FUL) 3Q16 revenue would be $534.8 million, but it came in at $512.9 million.

    By Peter Neil
  • uploads///FCF
    Basic Materials

    Will Flotek Industries’ Capital Expenditure Rise in 2017?

    In this article, we’ll analyze how Flotek Industries’ (FTK) operating cash flows have trended over the past few quarters.

    By Alex Chamberlin
  • uploads///Segment Revenues
    Basic Materials

    What Could Fuel Flotek Industries after 2Q16?

    From 2Q15 to 2Q16, all of Flotek Industries’ (FTK) segments except for the Consumer and Industrial Chemical Technologies segment saw lower revenues.

    By Alex Chamberlin
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.